Morgan Stanley raised the firm’s price target on Elanco (ELAN) to $22 from $18 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Closing Bell Movers: Ford nudges higher raised outlook, EV charge
- Elanco CEO buys $478.5K, CFO buys $150.4K in common stock
- Elanco Animal Health: Strategic Dual Channel Focus and Robust Innovation Pipeline Drive Buy Rating
- Elanco Animal Health: Hold Rating Amid Strategic Growth Plans and Execution Risks
- Elanco Animal Health Announces Restructuring Plan for Growth